Evidence map›Paper›PMID 41939739›Full record

ArticleFrontiers in medicine2026

Teprotumumab N01 for thyroid eye disease in China: clinical outcomes and quantitative MRI correlations.

Qiuyu Wang, Junning Cheng, Chunhui Yang, Jian Song, Yuqing Chen, Ya Shen, Lefeng Qu, Ruili Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qiuyu Wang *Department of Ophthalmology, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Junning Cheng *Department of Vascular and Endovascular Surgery, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Chunhui Yang *Department of Ophthalmology, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Jian SongDepartment of Ophthalmology, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Yuqing ChenDepartment of Ophthalmology, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Ya ShenDepartment of Ophthalmology, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Lefeng QuDepartment of Vascular and Endovascular Surgery, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Ruili WeiDepartment of Ophthalmology, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Teprotumumab is an IGF-1R-targeted therapy for thyroid eye disease (TED). In routine practice, response assessment remains challenging and standardized imaging biomarkers are lacking. Objective: To evaluate the real-world effectiveness of domestically produced teprotumumab N01 injection (SYCUME®) in Chinese patients with TED and to identify inferior rectus (IR)-focused quantitative MRI measures associated with changes in proptosis and disease activity. Methods: We conducted a retrospective real-world study of patients with active moderate-to-severe TED who completed a full course of teprotumumab N01 between March and December 2025. Orbital MRI was acquired before and after treatment. IR, lacrimal gland (LG), and orbital fat (OF) were obtained using ROI-based analysis on MAGiC (T1, T2, proton density) and IDEAL-IQ (fat fraction). MRI proptosis and coronal morphologic measures were quantified in 3D Slicer. Eye-level changes and associations between clinical outcomes and MRI parameter changes ( Results: Twenty-two patients (44 orbits) were analyzed. Hertel proptosis and CAS decreased after treatment (both Conclusion: In this real-world Chinese cohort, teprotumumab N01 was associated with concordant clinical improvement and quantitative MRI changes. IR-focused morphologic measures and diffusion-derived ADC showed the most consistent associations with changes in proptosis and disease activity, supporting their further evaluation for treatment monitoring in TED.

Indexed as

inferior rectusmagnetic resonance imagingreal-world studyteprotumumabthyroid eye disease

Identifiers

PMID41939739
PMCPMC13046536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.